Check out IMM ASX price sensitive announcements
25/3/20 and 26/3/20
PFS data released on above and didn't meet overall statistical significance.
Subsets of <65yrs and low monocytes patients did particularly well. Which was encouraging and trial continued to measure OS data which is being presented next week at SITC.
The gold standard of clinical trial outcome is overall survival. PFS was likely chosen to expedite product development.
Interstate comment you made on TLX.
"green is not good when you are accumulating!'
Could I ask everyone, please ignore these encouraging results.....until after I have had a chance to buy more'
Got you sussed Contra. Classic.
Media, page-306
-
- There are more pages in this discussion • 438 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |